Another advantage of dinaciclib is that it induces apoptosis in CLL cells irrespective of the presence of traditionally negative prognostic factors like unmutated Ig heavy chain V-III region VH26 (IGHV), prior fludarabine exposure, or del (17p13.1) status50. Here, SLC3A2 is linked to B-cell chronic lymphocytic leukemia.